siRNA Duplex Silencing Ugt2b1 for Diabetes Glucose Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes are costly, physically damaging, and lack effective long-lasting solutions, necessitating the development of new therapeutic agents like siRNA to target Ugt2b1 gene expression for reducing uridine 5′-diphospho-glucuronosyltransferase (UGT) levels.
Innovation Solution
Administering a medical composition containing siRNA that specifically targets and inhibits the Ugt2b1 gene expression, forming a sense and anti-sense RNA duplex to reduce UGT levels, thereby decreasing blood glucose levels and treating diabetes with fewer side effects and economic burdens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional medications are used to treat diabetes, then diabetes can be treated, but medical expenses become huge and physical damage occurs
Solution Approach 1:
The patent replaces conventional chemical medications with siRNA-based therapy, substituting a molecular biology mechanism (RNA interference) for traditional pharmacological approaches. This substitution achieves diabetes treatment by silencing the Ugt2b1 gene to reduce UGT enzyme levels, thereby lowering blood glucose without the severe side effects and high costs associated with conventional medications
Solution Approach 2:
The patent changes the fundamental treatment parameter from chemical inhibition to gene expression silencing. By targeting the Ugt2b1 gene at the transcriptional level rather than using chemical drugs that inhibit enzyme activity, the treatment achieves sustained glucose control with reduced physical damage and lower long-term medical expenses
2Reliability
If new diabetes treatments are developed, then treatment effectiveness may improve, but development time and complexity increase
Solution Approach 1:
The patent extracts and targets a specific gene (Ugt2b1) that is responsible for UGT enzyme production, which in turn is responsible for blood glucose regulation. By isolating and targeting this single gene rather than attempting to modulate complex metabolic pathways, the invention simplifies the development process while achieving effective diabetes treatment
Solution Approach 2:
The patent uses siRNA as an intermediary molecule that mediates between the therapeutic goal (reducing blood glucose) and the molecular target (Ugt2b1 gene). This intermediary approach simplifies development by providing a direct, predictable mechanism: the siRNA sequence can be designed to match the target gene, and the RNAi mechanism automatically handles the rest of the process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The siRNA effectively silences the Ugt2b1 gene, reducing UGT levels and blood glucose, providing a less invasive and more economical treatment for diabetes with high biological specificity and long-lasting effects.
Implementation Method 1
The sense and anti-sense RNA strands may form an RNA duplex
Implementation Method 2
Therapeutic approaches based on siRNA involve the introduction of a synthetic siRNA into the subject to elicit RNA interference (RNAi), thereby inhibiting the mRNA expression of a specific gene
Data Source
AI summary
Compositions and methods for treating a subject are provided. The compositions may include a short interfering RNA (siRNA) molecule comprising a sense RNA strand and an anti-sense RNA strand, the sense and anti-sense RNA strands forming an RNA duplex. The method may include administering a medical composition including an agent to the subject, wherein the agent is configured to reduce uridine 5′-diphospho-glucuronosyltransferase (UGT) levels in the subject. The sense RNA strand or the anti-sense RNA strand may be 15 to 25 nucleotides in length. The sense RNA strand and the anti-sense RNA strand may be 70%-100% complementary.